Put companies on watchlist
CompuGroup Medical SE & Co. KGaA
ISIN: DE000A288904
WKN: A28890
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

CompuGroup Medical SE & Co. KGaA · ISIN: DE000A288904 · EQS - Company News (90 News)
Country: Germany · Primary market: Germany · EQS NID: 1741763
05 October 2023 08:25AM

CompuGroup Medical bundles data-based solutions with ambulatory information systems and appoints Daniela Hommel as CFO


EQS-News: CompuGroup Medical SE & Co. KGaA / Key word(s): Personnel
CompuGroup Medical bundles data-based solutions with ambulatory information systems and appoints Daniela Hommel as CFO

05.10.2023 / 08:25 CET/CEST
The issuer is solely responsible for the content of this announcement.


CompuGroup Medical bundles data-based solutions with ambulatory information systems and appoints Daniela Hommel as CFO

 

  • CGM integrates business activities of the CHS segment into the AIS segment
  • Managing Director Consumer Health Management Information Systems Dr. Eckart Pech leaves CGM at his own request at the end of March 2024 after successfully building-up the data business
  • Administrative Board appoints Daniela Hommel as Chief Financial Officer effective March 2024


CompuGroup Medical SE & Co. KGaA (CGM), one of the world's leading e-health providers, continues to drive forward the customer focus of its digital solutions and the use of Artificial Intelligence (AI). Core activities are bundled especially for CGM customers in order to drive digitization in healthcare even faster. Studies show that for every hour doctors and their teams can devote to patients, they spend three to four hours on administrative work. AI-based solutions can significantly reduce such inefficiencies in healthcare for the benefit of patients. In order to provide the best possible support for customers, the business activities in the CHS segment will be integrated in the AIS segment going forward.

Dr. Eckart Pech, Managing Director Consumer & Health Management Information Systems, is leaving the company at his own request as of March 2024 after the successful build-up phase of the data business. Since joining the company in November 2019, Eckart Pech had initially driven the expansion of the telematics infrastructure in Germany. With the increasing relevance of data usage to support physicians, he was responsible for the establishment and successful expansion of the data business.

Also effective as of March 2024, the Board of Directors appoints Daniela Hommel as Chief Financial Officer. Daniela Hommel has held various finance and controlling positions in the Fresenius Group since 2012. Since 2018 she was responsible for the performance of the Fresenius Helios segment as Chief Financial Officer. In 2022, she assumed the role of Chief Financial and Innovation Officer of Helios Global Health GmbH with the aim of improving access to healthcare worldwide with new forms of care. In addition, she has assumed business responsibility for Fresenius' digital daughter Curalie as CEO since 2022. Prior to that, she spent 14 years at KPMG, most recently as the responsible audit partner in the healthcare sector. Until she joins CompuGroup Medical, CEO Michael Rauch will continue to be responsible for the CFO role on an interim basis.

Frank Gotthardt, founder of CGM and Chairman of the Board of Directors, commented, "CGM remains a driver of digitization in healthcare, both nationally and internationally. Data-based solutions and artificial intelligence will play a decisive role in the future. With Daniela Hommel, we are gaining an excellent financial expert with experience in the healthcare sector. I would like to expressly thank Eckart Pech for his important contributions to CGM's success, especially in building data-based solutions. We wish him all the best for the future."

Michael Rauch adds: "While integrating the CHS business activities into the AIS segment, the focus is on the added value for physicians, whom we support in the digitization of healthcare. I look forward to working with Daniela Hommel, thank Eckart Pech for the excellent collaboration over the past four years and wish him all the best as well."


About CompuGroup Medical SE & Co. KGaA

CompuGroup Medical is one of the leading e-health companies in the world. With a revenue base of EUR 1.130 billion in 2022, its software products are designed to support all medical and organizational activities in doctors’ offices, pharmacies, laboratories, hospitals and social welfare institutions. Its information services for all parties involved in the healthcare system and its web-based personal health records contribute towards safer and more efficient healthcare. CompuGroup Medical’s services are based on a unique customer base of more than 1.6 million users, including doctors, dentists, pharmacists and other healthcare professionals in inpatient and outpatient facilities. With locations in 21 countries and products in 60 countries worldwide, CompuGroup Medical is the e-health company with one of the highest coverages among healthcare professionals. More than 9,200 highly qualified employees support customers with innovative solutions for the steadily growing demands of the healthcare system.



05.10.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: CompuGroup Medical SE & Co. KGaA
Maria Trost 21
56070 Koblenz
Germany
Phone: +49 (0)160 3630362
Fax: +49 (0)261 8000 3200
E-mail: investor@cgm.com
Internet: www.cgm.com
ISIN: DE000A288904
WKN: A28890
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1741763

 
End of News EQS News Service

1741763  05.10.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1741763&application_name=news&site_id=boersengefluester
Visual performance / price development - CompuGroup Medical SE & Co. KGaA
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.